| Ticker: NMTI | 263 Summer Street | |
| Exchange: NASDAQ-National Market | Boston, Massachusetts 02210 | |
| Industry: Manufacturing | (617) 737-0930 |
| Type of Shares: | Common Shares | Filing Date: | 6/21/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 9/27/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $9.00 - $12.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $11.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.77 | |
| Offering Amount: | $31,500,000 | Selling: | $0.46 | |
| Expenses: | $700,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,985,922 |
| Manager | Tier | Phone |
| J.P. Morgan Securities Inc. | Lead Manager | (212) 648-9922 |
| CS First Boston | Co-manager | (212) 909-3312 |
| Jefferies & Company Incorporated | Co-manager | (800) 933-6656 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $3.83 | $1.36 | $0.71 | Assets: | $8.64 |
| Net Income: | $0.58 | -$1.13 | $0.13 | Liabilities: | $2.00 |
| EPS: | $0.08 | -$0.17 | $0.02 | Equity: | $6.65 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops and markets innovative medical devices that utilize advanced materials and are delivered by minimally invasive procedures. The company's patented medical devices include self-expanding stents and septal repair devices. At this time, the Company's stents are marketed in the United States and abroad, and the Company is completing the development of its septal repair device. NMT has developed an expertise in precisely engineering nitinol and other advanced materials for a variety of innovative medical device applications. Nitinol is a nickel-titanium alloy that exhibits unique superelastic and thermal shape-memory characteristics which enable the Company's nitinol-based medical devices to transform into their intended shape once deployed into the body. The Company has developed capabilities in advanced device fabrication, materials characterization, manufacturing and process control and sophisticated in vitro testing resulting in highly efficient and reliable manufacturing processes. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used for the redemption of the Redeemable Preferred Stock and funding of research, development, clinical trials and regulatory matters, leasehold improvements and equipment, potential licenses and acquisitions of technologies or products that complement NMT's business and for other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.